- Policy
- Will Opdivo soon be reimb as first-line gastric cancer Tx?
- by Lee, Tak-Sun Aug 17, 2023 05:29am
- Whether Ono Pharmaceutical Korea’s ‘Opdivo Inj’ will receive reimbursement as the first first-line immunotherapy option for gastric cancer is gaining attention. If the drug is reimbursed as a first-line treatment for gastric cancer, Opdivo Inj may closely chase the sales of Keytruda, which had expanded coverage as a first-line treatment
- Policy
- ₩176.5 bil was spent on atopic dermatitis every year
- by Kim, Jung-Ju Aug 16, 2023 05:37am
- The National Health Insurance medical expenditures spent by patients with atopic dermatitis have risen every year to record KRW 176.5 billion last year. This is a 114.4% rise in 5 years. By age group, patients in their 20s accounted for 34.1% of the total expenditures, followed by those in their 30s (18.9%), then those in their 40s (11.8%).
- Policy
- Will it be possible to cover 'obesity drugs'?
- by Lee, Jeong-Hwan Aug 16, 2023 05:37am
- Attention is focusing on whether health insurance coverage standards for obesity treatment drugs, which are classified as non-reimbursed drugs that are not covered by health insurance, can be established. The Ministry of Health and Welfare announced that it had started discussions with the Korean Society of Obesity to discuss the necessity of
- Policy
- In order to activate new drugs & raw materials in Korea
- by Lee, Tak-Sun Aug 11, 2023 05:36am
- Opinions were suggested that in order to further promote domestically developed new drugs and domestically produced raw materials, preferential drug prices are necessary. For new drugs developed domestically, the additional system should be used more actively and reference prices should be given to support exports. In order to increase the 2
- Policy
- GPP drug Spevigo is first approved in Korea
- by Lee, Hye-Kyung Aug 11, 2023 05:36am
- The new orphan drug Spevigo (spesolimab) that is being imported by ‘Boehringer Ingelheim Korea has received domestic marketing authorization in Korea. The Ministry of Food and Drug Safety (Minister Yu-Kyung Oh) approved the new orphan drug Spevigo on the 9th. Generalized Pustular Psoriasis (GPP) is characterized by systemic inflamma
- Policy
- PVG-004 succeeded in securing BA as the 1st generic K-CAB
- by Lee, Jeong-Hwan Aug 11, 2023 05:35am
- On the 10th, Pharmavision announced that the PVG-004 (Tegoprazan) project, which had transferred technology to SCD, succeeded in securing equivalence in the K-CAB and BA test for the first time in Korea. The reexamination expiration date (PMS) for K-CAB is July 4, 2024. Substance patents expire on August 25, 2031, and crystalline patents expi
- Policy
- 'Apply preferential pricing to non-inferior new drugs'
- by Lee, Tak-Sun Aug 11, 2023 05:35am
- With the government planning to release a drug price reform plan that includes a fair value compensation plan for innovative new drugs as early as next month, attention is focused on whether the reform will include a preferential measure for new drugs that demonstrate non-inferiority. This is because most of the new drugs that domestic pharma
- Policy
- Health insurance finance approved by the government alone
- by Lee, Jeong-Hwan Aug 11, 2023 05:35am
- It was pointed out again that health insurance finance should be included in the national finance and operated as a fund. There are concerns that if the health insurance finances are managed without going through deliberation by the National Assembly as it is now, transparency will be reduced and it can lead to negligence. The current method
- Policy
- Out of stock of GLP-1 injections
- by Moon, sung-ho Aug 10, 2023 05:33am
- As the news of GLP-1 (Glucagon-like peptide-1)-type diabetes treatments being used in clinical settings is reported one after another, concerns about this are growing. According to the medical community on the 4th, Novo Nordisk Pharmaceutical Korea is currently informing the clinical site of the out-of-stock news of Xultophy, a GLP-1 series diab
- Policy
- MOHW to expand ‘approval-assessment-negotiation’ project
- by Moon, sung-ho Aug 9, 2023 05:49am
- With the pilot project for the parallel operation of the ‘approval-assessment-negotiation linkage’ system that was implemented to shorten the drug reimbursement process in full swing, additional drugs are expected to be selected for the project in 2H this year. This is because the health authorities started a demand survey to select additio
